Tag - VNRX

Developments

VolitionRx files patent for Ebola triage and treatment monitoring test

VolitionRx (NYSE AMERICAN: VNRX) has announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monitoring patients who are suspected of having contracted...

June 3, 2026

Developments

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...

March 6, 2026

Markets

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

March 14, 2018

Tag - VNRX

VolitionRx files patent for Ebola triage and treatment monitoring test

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx closes $8.4-million stock offering

Subscribe